Topic: spinal muscular atrophy
With a NICE nod for its spinal muscular atrophy treatment Spinraza, Biogen is hoping it can corner the market before competitors take the field.
As Novartis waits for FDA action on its SMA gene therapy Zolgensma, the company has rolled out yet another round of data on the drug.
Biogen CEO Michel Vounatsos was richly rewarded last year but is now facing pressure to come up with a new R&D plan.
On the cusp of FDA approval for its landmark SMA gene therapy Zolgensma, Novartis is investigating an infant's death in a European trial.
Novartis expects the FDA to decide on its spinal muscular atrophy gene therapy next month, but it’s already padding its case with new phase 3 data.
Novartis has said that a $4 million to $5 million price for its SMA gene therapy Zolgensma would be justified. The watchdogs at ICER disagree.
It's been a long slog through a sluggish launch, but Novartis' highly anticipated heart drug Entresto has finally reached blockbuster status.
After releasing strong earnings, Biogen's executives did their best to reassure analysts that the success of the pipeline won't rely solely on Alzheimer's.
Leerink analysts predict a doubling of competitive intensity in 15 disease areas by 2023, putting a dozen companies at risk.
Biogen outperformed this quarter, but analysts still worry about competition for Spinraza and an Alzheimer's candidate that hasn't yet proved out.